Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTR3B | O95264 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16256875 | 0.88 | GRM2 (0.51) | CNR2CNR1GRM2NTRK1NTRK2 | |
| SCHEMBL13603591 | 0.84 | GRM2 (0.50) | CNR2CNR1GRM2DRD4RORC | |
| SCHEMBL19664446 | 0.84 | GRM2 (0.53) | CNR2CNR1GRM2DRD4RORC | |
| SCHEMBL11955035 | 0.82 | GRM2 (0.49) | CNR2CNR1GRM2DRD4RORC | |
| SCHEMBL18090934 | 0.81 | GRM2 (0.48) | CNR2CNR1GRM2DRD4RORC | |
| SCHEMBL8651809 | 0.77 | ESR1 (0.48) | CNR2MEN1KMT2APKMKDM4E | |
| SCHEMBL10238327 | 0.76 | MEN1 (0.47) | CNR2CNR1GRM2MEN1KMT2A | |
| SCHEMBL8058929 | 0.76 | KDM4E (0.50) | GRM2MEN1KMT2APKMHTR3E | |
| SCHEMBL23507228 | 0.75 | POLB (0.50) | CNR2CNR1GRM2DRD4DRD2 | |
| SCHEMBL21698420 | 0.75 | CNR2 (0.42) | CNR2CNR1GRM2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10959984-B2 | Methods for treating cancer with RORγ inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-30 | — | — | US | disclosed |
| US-20180085348-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085348-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | RORB, RORA, RORC | CNR2 744/4885CNR1 611/4885GRM2 343/4885 |
| US-10959984-B2 | Methods for treating cancer with RORγ inhibitors | RORB, RORC, RORA | CNR2 420/4885CNR1 372/4885GRM2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.